BioLife Solutions Reports 25% Revenue Growth to $27.5 Million in Q1 2026

BioLife Solutions, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $27.5 million, a 25% increase from $22.1 million in the same period of 2025. The company's gross profit also rose to $17.5 million, up from $14.8 million, although the gross margin decreased slightly to 64% from 67%. This revenue growth was primarily driven by heightened customer demand for the company's biopreservation media products. However, the cost of revenue increased by 38% to $10 million, reflecting both the rise in sales and a shift towards lower-margin products.

In terms of operational changes, BioLife Solutions made strategic moves by acquiring the remaining 90% of PanTHERA CryoSolutions Inc. on April 4, 2025, enhancing its capabilities in biopreservation technology. The acquisition was valued at approximately $16.8 million, which included cash and stock components. Additionally, the company divested its SAVSU business, which was completed in October 2025, allowing it to focus on higher-margin revenue streams. The divestiture is reflected in the financial statements as a discontinued operation, with a net gain of $10.3 million recognized from the sale.

The company’s operational metrics showed a notable increase in customer engagement, with accounts receivable rising to $13.1 million from $8 million year-over-year, indicating a growing customer base. Employee headcount also increased due to the PanTHERA acquisition, contributing to a rise in research and development expenses, which surged by 84% to $2.7 million. This increase reflects the company's commitment to enhancing its product offerings and technological capabilities.

Despite the positive revenue growth, BioLife Solutions experienced a net income of $1.2 million for the first quarter of 2026, compared to a net loss of $448,000 in the prior year. The company attributed this turnaround to improved operational efficiencies and increased sales, although it also faced higher operating expenses, which rose by 14% to $17.5 million. The company’s liquidity position remains strong, with $111.5 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2026, sufficient to meet its operational needs for at least the next twelve months.

Looking ahead, BioLife Solutions anticipates continued growth driven by its expanded product portfolio and increased market demand for its biopreservation solutions. The company remains focused on leveraging its recent acquisitions to enhance its competitive position in the cell and gene therapy market, while also managing operational costs to improve profitability.